Evidence map›Paper›PMID 37111702›Full record

ArticlePharmaceutics2023

Stimuli-Responsive Double Single-Atom Catalysts for Parallel Catalytic Therapy.

Tushuai Li, Yue Gu, Lisha Yu, Shenglong Zhu, Jie Zhang, Yongquan Chen

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceutics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Tushuai LiSchool of Food Science and Technology, Jiangnan University, Wuxi 214013, China.
Yue GuKey Laboratory of Anti-Inflammatory and Immune Medicine, Ministry of Education, Institute of Clinical Pharmacology, Anhui Medical University, Hefei 230032, China.
Lisha YuSchool of Biology and Food Engineering, Changshu Institute of Technology, Suzhou 215500, China.
Shenglong ZhuSchool of Food Science and Technology, Jiangnan University, Wuxi 214013, China.
Jie ZhangSchool of Biology and Food Engineering, Changshu Institute of Technology, Suzhou 215500, China.ORCID 0000-0002-6903-4220
Yongquan ChenSchool of Food Science and Technology, Jiangnan University, Wuxi 214013, China.ORCID 0000-0003-4747-4708
Jiangnan University · CNSuzhou University of Technology · CNMinistry of Education of the People's Republic of China · CN

Funding

Jie Zhang BK20221091
6 · The paper itself

Abstract

Tumor microenvironment (TME)-induced nanocatalytic therapy is a trending strategy for tumor-targeting therapy, but the low catalytic efficiency remains to limit its therapeutic effect. The single-atom catalysts (SACs) appear as a novel type of nanozymes that possesses incredible catalytic activity. Here, we developed PEGylated manganese/iron-based SACs (Mn/Fe PSACs) by coordinating single-atom Mn/Fe to nitrogen atoms in hollow zeolitic imidazolate frameworks (ZIFs). Mn/Fe PSACs catalyze cellular hydrogen peroxide (H

Indexed as

reactive oxygen speciessingle-atom catalystssynergistic antitumortumor microenvironment

Identifiers

PMID37111702
PMCPMC10143931
OpenAlexW4365148560

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.